David Elashoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Elashoff has a total of 401 co-authors. Here are the top co-authors by number of shared publications:
- Edward Brian Garon
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
13 shared publications - Arash Naeim
Center for SMART Health, Clinical and Translational Science Institute, University of California, Los Angeles, 200 Medical Plaza Driveway, Suite 120, Los Angeles, CA 90095, United States
10 shared publications - Neil S. Wenger
Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine University of California Los Angeles California USA
10 shared publications - Tristan R. Grogan
Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
10 shared publications - Aaron Lisberg
University of California, Los Angeles 14 Los Angeles, CA
9 shared publications - Jonathan Wade Goldman
David Geffen School of Medicine at UCLA, Los Angeles, California
9 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in BMC Rheumatology
The association between visceral adipose tissue, serum urate, and hepatic fat deposition: a post-hoc analysis from the Habitual Diet vs. Avocado randomized control trial
Background: Hyperuricemia, while associated with, is not part of the metabolic syndrome. We sought to examine the association between central obesity as measured by visceral abdominal tissue (VAT) deposition and serum urate (SU). We further explored the association between SU and hepatic fat deposition (HFD). Methods: Through a post-hoc analysis, using a single study site from the Habitual Diet vs. Avocado (HAT) multi-center randomized control trial, baseline serum, abdominal magnetic resonance imaging (MRI) and responses to questionnaires were available. Means, medians and proportions were used to describe variables. Anova, and Chi-square were used to describe bivariate associations between VAT and SU as well as SU and HFD. Generalized linear models (linear or logistic) were used to describe above associations while controlling for other potential metabolic confounders. Principal component analyses were used to evaluate the fit of SU with the other metabolic variables. Trial registration: The parent habitual diet avocado trial was registered with clinical trials.gov with the following protocol, NCT03528031. Results: The baseline cohort of 223 subjects were mostly female (80%) with mean age of 46 years and BMI of 33, (65% were obese), 25% had high urate (SU > 360 µmol/L). SU was strongly correlated with VAT deposits ( r = 0.31, p 360 μmol/L were more likely to be male, obese (BMI > 30), morbidly obese (BMI > 40), and have greater amounts of VAT deposits. More than two-thirds (71%) of subjects with hyperuricemia had elevated HFD (HFD > 5%) compared to 41% of subjects with normal SU (p < 0.0001). After controlling for potential confounding covariates, including BMI, the association between VAT and SU was attenuated potentially through mediating factors associated with covariates. SU > 360 μmol/L remained strongly associated with HFD > 5%, (Odds Ratio = 3.0, p = 0.005) after adjusting for BMI and other confounders. Conclusions: For this cohort of subjects with known central adiposity, higher SU levels were associated with greater deposits of VAT strengthening the association between SU > 360 μmol/L and metabolic syndrome. SU > 360 μmol/L was also associated with higher proportion of HFD. As a limitation of this post-hoc cross-sectional design, causation (or directionality) cannot be assumed. The parent HAT clinical trial was registered under the approved clinical trial protocol, NCT03528031. Original submission, 04 May 2018. Final version, 17 March 2023.
- 15 October 2026
- Published by Springer Nature in BMC Rheumatology
Open AccessThe association between visceral adipose tissue, serum urate, and hepatic fat deposition: a post-hoc analysis from the Habitual Diet vs. Avocado randomized control trial
Background: Hyperuricemia, while associated with, is not part of the metabolic syndrome. We sought to examine the association between central obesity as measured by visceral abdominal tissue (VAT) deposition and serum urate (SU). We further explored the association between SU and hepatic fat deposition (HFD). Methods: Through a post-hoc analysis, using a single study site from the Habitual Diet vs. Avocado (HAT) multi-center randomized control trial, baseline serum, abdominal magnetic resonance imaging (MRI) and responses to questionnaires were available. Means, medians and proportions were used to describe variables. Anova, and Chi-square were used to describe bivariate associations between VAT and SU as well as SU and HFD. Generalized linear models (linear or logistic) were used to describe above associations while controlling for other potential metabolic confounders. Principal component analyses were used to evaluate the fit of SU with the other metabolic variables. Trial registration: The parent habitual diet avocado trial was registered with clinical trials.gov with the following protocol, NCT03528031. Results: The baseline cohort of 223 subjects were mostly female (80%) with mean age of 46 years and BMI of 33, (65% were obese), 25% had high urate (SU > 360 µmol/L). SU was strongly correlated with VAT deposits ( r = 0.31, p 360 μmol/L were more likely to be male, obese (BMI > 30), morbidly obese (BMI > 40), and have greater amounts of VAT deposits. More than two-thirds (71%) of subjects with hyperuricemia had elevated HFD (HFD > 5%) compared to 41% of subjects with normal SU (p < 0.0001). After controlling for potential confounding covariates, including BMI, the association between VAT and SU was attenuated potentially through mediating factors associated with covariates. SU > 360 μmol/L remained strongly associated with HFD > 5%, (Odds Ratio = 3.0, p = 0.005) after adjusting for BMI and other confounders. Conclusions: For this cohort of subjects with known central adiposity, higher SU levels were associated with greater deposits of VAT strengthening the association between SU > 360 μmol/L and metabolic syndrome. SU > 360 μmol/L was also associated with higher proportion of HFD. As a limitation of this post-hoc cross-sectional design, causation (or directionality) cannot be assumed. The parent HAT clinical trial was registered under the approved clinical trial protocol, NCT03528031. Original submission, 04 May 2018. Final version, 17 March 2023.
- 8 July 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (8) , e014647
Clinical Triage of Individuals With Warning Symptoms of Imminent Cardiac Arrest
BACKGROUND: At least 50% of individuals who suffer sudden cardiac arrest (SCA) have warning symptoms before their SCA, but these are not sufficient to predict imminent SCA (ISCA). We hypothesized that combining symptoms with clinical profile could effectively predict ISCA. METHODS: In 2 community-based studies of SCA in Oregon and California, survivors of SCA who had experienced warning symptoms and called 911 (n=364) were compared with control subjects (n=313) who also called 911 for similar symptoms but did not have SCA. Symptom information was obtained directly from interviews as well as prehospital emergency records. We used machine learning to identify predictive combinations of symptoms and clinical features in this case-control study. The area under the receiver operating characteristic curve (AUC) and 5-fold cross-validation were used to assess model performance and stability. RESULTS: Warning symptom-clinical profile combinations were successfully identified. The combination of chest pain and known heart failure predicted ISCA among males, while chest pain and known coronary artery disease predicted ISCA among females (AUC=0.788). With dyspnea, both history of coronary artery disease and heart failure were predictors (AUC=0.745). In the absence of chest pain or dyspnea, seizure-like symptoms, coronary artery disease, and heart failure were predictors (AUC, 0.775). 5-fold cross-validation produced consistent results. CONCLUSIONS: Combinations of warning symptoms and clinical features distinguished individuals with SCA from individuals without SCA with good accuracy (AUCs, 0.745–0.788). These findings have implications for clinical triage of ISCA warning symptoms in emergency settings and warrant investigation in larger studies.
- 8 July 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (8) , e014647
Clinical Triage of Individuals With Warning Symptoms of Imminent Cardiac Arrest
BACKGROUND: At least 50% of individuals who suffer sudden cardiac arrest (SCA) have warning symptoms before their SCA, but these are not sufficient to predict imminent SCA (ISCA). We hypothesized that combining symptoms with clinical profile could effectively predict ISCA. METHODS: In 2 community-based studies of SCA in Oregon and California, survivors of SCA who had experienced warning symptoms and called 911 (n=364) were compared with control subjects (n=313) who also called 911 for similar symptoms but did not have SCA. Symptom information was obtained directly from interviews as well as prehospital emergency records. We used machine learning to identify predictive combinations of symptoms and clinical features in this case-control study. The area under the receiver operating characteristic curve (AUC) and 5-fold cross-validation were used to assess model performance and stability. RESULTS: Warning symptom-clinical profile combinations were successfully identified. The combination of chest pain and known heart failure predicted ISCA among males, while chest pain and known coronary artery disease predicted ISCA among females (AUC=0.788). With dyspnea, both history of coronary artery disease and heart failure were predictors (AUC=0.745). In the absence of chest pain or dyspnea, seizure-like symptoms, coronary artery disease, and heart failure were predictors (AUC, 0.775). 5-fold cross-validation produced consistent results. CONCLUSIONS: Combinations of warning symptoms and clinical features distinguished individuals with SCA from individuals without SCA with good accuracy (AUCs, 0.745–0.788). These findings have implications for clinical triage of ISCA warning symptoms in emergency settings and warrant investigation in larger studies.
- Open Access
- 15 June 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (3) , rkag080
Relative muscle mass is preserved during weight loss in rheumatoid arthritis: a post-hoc RCT analysis
Objectives: Obesity and sarcopenia commonly coexist in RA, compounding metabolic risk and disability. Intentional weight loss may improve outcomes but raises concern for accelerated muscle loss. We conducted a post-hoc analysis of a randomized controlled trial (RCT) of a hypocaloric, high-protein diet in adults with RA and obesity to determine whether diet-induced weight loss was associated with disproportionate reductions in muscle mass. Methods: Adults with RA and obesity were randomized to a 12-week hypocaloric, high-protein diet or to control dietary advice (NCT02881307). DXA was performed at baseline and 12 weeks. Fat mass index (FMI), appendicular lean mass index (ALMI) and adiposity-adjusted ALMI (ALMIFMI) were derived and standardized to Z-scores using national reference data. Between-group differences in change were compared using t-tests, with FDR-adjusted P values reported for all analyses. Results: Participants in the dietary intervention achieved significant reductions in total fat mass (mean change in FMI Z-score −0.35 vs 0.04; P = 0.003). Changes in ALMI Z-score (−0.37 vs −0.43; P = 0.92) and ALMIFMI Z-score (−0.15 vs −0.55; P = 0.92) did not differ significantly between groups. In the intervention group there was minimal decline in ALMFMI, suggesting parallel reductions in lean and fat tissue. Conclusion: In adults with RA and obesity, diet-induced weight loss reduced adiposity without evidence of disproportionate muscle loss. These findings support the safety of structured, protein-adequate weight-loss interventions in this population.
- 15 June 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (3) , rkag080
Open AccessRelative muscle mass is preserved during weight loss in rheumatoid arthritis: a post-hoc RCT analysis
Objectives: Obesity and sarcopenia commonly coexist in RA, compounding metabolic risk and disability. Intentional weight loss may improve outcomes but raises concern for accelerated muscle loss. We conducted a post-hoc analysis of a randomized controlled trial (RCT) of a hypocaloric, high-protein diet in adults with RA and obesity to determine whether diet-induced weight loss was associated with disproportionate reductions in muscle mass. Methods: Adults with RA and obesity were randomized to a 12-week hypocaloric, high-protein diet or to control dietary advice (NCT02881307). DXA was performed at baseline and 12 weeks. Fat mass index (FMI), appendicular lean mass index (ALMI) and adiposity-adjusted ALMI (ALMIFMI) were derived and standardized to Z-scores using national reference data. Between-group differences in change were compared using t-tests, with FDR-adjusted P values reported for all analyses. Results: Participants in the dietary intervention achieved significant reductions in total fat mass (mean change in FMI Z-score −0.35 vs 0.04; P = 0.003). Changes in ALMI Z-score (−0.37 vs −0.43; P = 0.92) and ALMIFMI Z-score (−0.15 vs −0.55; P = 0.92) did not differ significantly between groups. In the intervention group there was minimal decline in ALMFMI, suggesting parallel reductions in lean and fat tissue. Conclusion: In adults with RA and obesity, diet-induced weight loss reduced adiposity without evidence of disproportionate muscle loss. These findings support the safety of structured, protein-adequate weight-loss interventions in this population.
- Open Access
- 31 January 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (3) , 1667-1676
Rheumatoid arthritis in crisis: investigating the impact of stress on RA flares during the COVID-19 pandemic
Introduction/objectives: Psychological stress impacts rheumatoid arthritis (RA) disease activity, and California’s response to the COVID-19 pandemic created historically significant stressors for patients. This study examined factors associated with changes in RA flares during the pandemic. Methods: In this cross-sectional COVID-19 RA study, patients with RA ICD-9/10 codes were emailed a questionnaire in July/November of 2020 containing questions on RA disease activity, Routine Assessment of Patient Index Data 3 (RAPID3), flare number and frequency, RA Flare Questionnaire (RA-FQ), Perceived Stress Scale 4 (PSS-4), stressors, and demographics. Age, anti-cyclic citrullinated antibody, and rheumatoid factor were extracted from medical records. Analyses examined associations between current flare status, number of flares, and changes in flare frequency with PSS-4 and stressors. Results: Of 1138 respondents (22.6% response rate), 69.3% reported at least one RA flare, 43% multiple flares, and 36.3% currently experiencing a flare. Compared to pre-pandemic levels, 36.3% noted more frequent flares, while 9.2% reported fewer. Increased stress was noted across all flare groups. Regression analyses revealed significant associations between current flare and PSS-4 scores, financial stress, and sleep quality (all p < 0.03). A higher number of flares were significantly associated with PSS-4, financial stress, and home stress ( p < 0.03). Increased flare frequency was associated with PSS-4, apprehension, panic, financial stress, and sleep quality (all p < 0.05). Asian race was negatively associated with the number of flares and flare frequency (both p < 0.05). Conclusions: This study reports a link between stress and RA flares during the pandemic, underscoring the need for targeted strategies to manage RA patients at risk of flare during heightened stress. Key Points • During the COVID-19 pandemic, patient-reported RA flares increased significantly compared to pre-pandemic levels, signifying there may be value in reevaluating RA management strategies during periods of heightened stress. • Financial stress, home stress, and poor sleep were major pandemic stressors linked to current and increased frequency of RA flares. • RA patients not in remission may be more susceptible to disease exacerbations while under stress, as those experiencing flares during the pandemic were less likely to have been in remission beforehand. • Asian race was associated with fewer RA flares and reduced flare frequency, suggesting racial and ethnic differences may influence flare patterns.
- 31 January 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (3) , 1667-1676
Open AccessRheumatoid arthritis in crisis: investigating the impact of stress on RA flares during the COVID-19 pandemic
Introduction/objectives: Psychological stress impacts rheumatoid arthritis (RA) disease activity, and California’s response to the COVID-19 pandemic created historically significant stressors for patients. This study examined factors associated with changes in RA flares during the pandemic. Methods: In this cross-sectional COVID-19 RA study, patients with RA ICD-9/10 codes were emailed a questionnaire in July/November of 2020 containing questions on RA disease activity, Routine Assessment of Patient Index Data 3 (RAPID3), flare number and frequency, RA Flare Questionnaire (RA-FQ), Perceived Stress Scale 4 (PSS-4), stressors, and demographics. Age, anti-cyclic citrullinated antibody, and rheumatoid factor were extracted from medical records. Analyses examined associations between current flare status, number of flares, and changes in flare frequency with PSS-4 and stressors. Results: Of 1138 respondents (22.6% response rate), 69.3% reported at least one RA flare, 43% multiple flares, and 36.3% currently experiencing a flare. Compared to pre-pandemic levels, 36.3% noted more frequent flares, while 9.2% reported fewer. Increased stress was noted across all flare groups. Regression analyses revealed significant associations between current flare and PSS-4 scores, financial stress, and sleep quality (all p < 0.03). A higher number of flares were significantly associated with PSS-4, financial stress, and home stress ( p < 0.03). Increased flare frequency was associated with PSS-4, apprehension, panic, financial stress, and sleep quality (all p < 0.05). Asian race was negatively associated with the number of flares and flare frequency (both p < 0.05). Conclusions: This study reports a link between stress and RA flares during the pandemic, underscoring the need for targeted strategies to manage RA patients at risk of flare during heightened stress. Key Points • During the COVID-19 pandemic, patient-reported RA flares increased significantly compared to pre-pandemic levels, signifying there may be value in reevaluating RA management strategies during periods of heightened stress. • Financial stress, home stress, and poor sleep were major pandemic stressors linked to current and increased frequency of RA flares. • RA patients not in remission may be more susceptible to disease exacerbations while under stress, as those experiencing flares during the pandemic were less likely to have been in remission beforehand. • Asian race was associated with fewer RA flares and reduced flare frequency, suggesting racial and ethnic differences may influence flare patterns.
- Open Access
- 20 November 2024
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 08 (04) , 1-11
A Phase I/II Randomized Trial of Higher Dose mRNA-1273 Boosters in Lung Transplant Recipients
Higher-dose mRNA booster vaccines have not been well studied for transplant recipients. This study evaluated the safety, reactogenicity and immunogenicity of higher dose mRNA-1273 booster vaccines among lung transplant recipients (LTRs). This phase 1/2 open-label randomized clinical trial of higher-dose mRNA-1273 booster vaccination enrolled nineteen adult LTRs into the 50 µg (n = 8) vs. 100 µg (n = 11) groups before enrollment was terminated due to the availability of the bivalent mRNA-1273.222 vaccine. Local and systemic reactogenicity was predominantly mild or moderate in severity for both dose groups, mostly limited to pain at the injection site, fatigue and headache. Humoral and cellular immune responses were weak. Overall, 75% and 64% of the 50 µg and 100 µg groups had detectable neutralizing antibodies on Day 30 (vs. 63% and 55% on Day 1), respectively. On Day 30, 50% and 55% had detectable spike-specific CD4+ IFNγ responses (vs. 29% and 36% on Day 1), and 50% and 36% had detectable CD8+ IFNγ responses (vs. 29% and 45% on Day 1) for the two groups, respectively. LTRs have reactogenicity and immune responses that are attenuated compared with the non-immunocompromised population. Administration of higher doses in solid organ transplant patients may be warranted. Clinical trial NCT05280158.
- 20 November 2024
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 08 (04) , 1-11
Open AccessA Phase I/II Randomized Trial of Higher Dose mRNA-1273 Boosters in Lung Transplant Recipients
Higher-dose mRNA booster vaccines have not been well studied for transplant recipients. This study evaluated the safety, reactogenicity and immunogenicity of higher dose mRNA-1273 booster vaccines among lung transplant recipients (LTRs). This phase 1/2 open-label randomized clinical trial of higher-dose mRNA-1273 booster vaccination enrolled nineteen adult LTRs into the 50 µg (n = 8) vs. 100 µg (n = 11) groups before enrollment was terminated due to the availability of the bivalent mRNA-1273.222 vaccine. Local and systemic reactogenicity was predominantly mild or moderate in severity for both dose groups, mostly limited to pain at the injection site, fatigue and headache. Humoral and cellular immune responses were weak. Overall, 75% and 64% of the 50 µg and 100 µg groups had detectable neutralizing antibodies on Day 30 (vs. 63% and 55% on Day 1), respectively. On Day 30, 50% and 55% had detectable spike-specific CD4+ IFNγ responses (vs. 29% and 36% on Day 1), and 50% and 36% had detectable CD8+ IFNγ responses (vs. 29% and 45% on Day 1) for the two groups, respectively. LTRs have reactogenicity and immune responses that are attenuated compared with the non-immunocompromised population. Administration of higher doses in solid organ transplant patients may be warranted. Clinical trial NCT05280158.
- Open Access
Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins
Objective Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We aimed to investigate how different biologic therapies affect levels of PON1 and oxylipins. Methods 1213 adult patients with RA in the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory CoNditions cohort study with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) >10) who initiated a new biologic (tocilizumab (TCZ), n=296; abatacept, n=374; tumour necrosis factor inhibitors, n=427; rituximab, n=116) were followed prospectively with serum specimens analysed for PON1 activity by arylesterase (ARYL), lactonase (LAC) and PON assays at baseline and after 6 months of biologic therapy. A targeted panel of oxylipins was evaluated by liquid chromatography-mass spectrometry/mass spectrometry in a subset of patients with the lowest and highest 6-month Disease Activity Score 28 (DAS28)-C reactive protein (CRP) responses in each treatment group. Results PON1 activity generally increased in the entire cohort after 6 months of new biologic therapy, showing the greatest, most consistent increases in the TCZ group. Increases in all three PON1 domains associated with significant decreases in disease activity in DAS28-CRP/CDAI (pConclusion Improvement in disease activity across four classes of biologics is associated with enhanced PON1 activity, which has significant implications for cardiovascular safety.
Open AccessDisease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins
Objective Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We aimed to investigate how different biologic therapies affect levels of PON1 and oxylipins. Methods 1213 adult patients with RA in the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory CoNditions cohort study with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) >10) who initiated a new biologic (tocilizumab (TCZ), n=296; abatacept, n=374; tumour necrosis factor inhibitors, n=427; rituximab, n=116) were followed prospectively with serum specimens analysed for PON1 activity by arylesterase (ARYL), lactonase (LAC) and PON assays at baseline and after 6 months of biologic therapy. A targeted panel of oxylipins was evaluated by liquid chromatography-mass spectrometry/mass spectrometry in a subset of patients with the lowest and highest 6-month Disease Activity Score 28 (DAS28)-C reactive protein (CRP) responses in each treatment group. Results PON1 activity generally increased in the entire cohort after 6 months of new biologic therapy, showing the greatest, most consistent increases in the TCZ group. Increases in all three PON1 domains associated with significant decreases in disease activity in DAS28-CRP/CDAI (pConclusion Improvement in disease activity across four classes of biologics is associated with enhanced PON1 activity, which has significant implications for cardiovascular safety.
- Open Access
Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models
Manuka honey (MH) exhibits potential antitumor activity in preclinical models of a number of human cancers. Treatment in vitro with MH at concentrations ranging from 0.3 to 5.0% (w/v) led to significant dose-dependent inhibition of proliferation of human breast cancer MCF-7 cells, but anti-proliferative effects of MH were less pronounced in MDA-MB-231 breast cancer cells. Effects of MH were also tested on non-malignant human mammary epithelial cells (HMECs) at 2.5% w/v, and it was found that MH reduced the proliferation of MCF-7 cells but not that of HMECs. Notably, the antitumor activity of MH was in the range of that exerted by treatment of MCF-7 cells with the antiestrogen tamoxifen. Further, MH treatment stimulated apoptosis of MCF-7 cells in vitro, with most cells exhibiting acute and significant levels of apoptosis that correlated with PARP activation. Additionally, the effects of MH induced the activation of AMPK and inhibition of AKT/mTOR downstream signaling. Treatment of MCF7 cells with increased concentrations of MH induced AMPK phosphorylation in a dose-dependent manner that was accompanied by inhibition of phosphorylation of AKT and mTOR downstream effector protein S6. In addition, MH reduced phosphorylated STAT3 levels in vitro, which may correlate with MH and AMPK-mediated anti-inflammatory properties. Further, in vivo, MH administered alone significantly inhibited the growth of established MCF-7 tumors in nude mice by 84%, resulting in an observable reduction in tumor volume. Our findings highlight the need for further research into the use of natural compounds, such as MH, for antitumor efficacy and potential chemoprevention and investigation of molecular pathways underlying these actions.
Open AccessManuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models
Manuka honey (MH) exhibits potential antitumor activity in preclinical models of a number of human cancers. Treatment in vitro with MH at concentrations ranging from 0.3 to 5.0% (w/v) led to significant dose-dependent inhibition of proliferation of human breast cancer MCF-7 cells, but anti-proliferative effects of MH were less pronounced in MDA-MB-231 breast cancer cells. Effects of MH were also tested on non-malignant human mammary epithelial cells (HMECs) at 2.5% w/v, and it was found that MH reduced the proliferation of MCF-7 cells but not that of HMECs. Notably, the antitumor activity of MH was in the range of that exerted by treatment of MCF-7 cells with the antiestrogen tamoxifen. Further, MH treatment stimulated apoptosis of MCF-7 cells in vitro, with most cells exhibiting acute and significant levels of apoptosis that correlated with PARP activation. Additionally, the effects of MH induced the activation of AMPK and inhibition of AKT/mTOR downstream signaling. Treatment of MCF7 cells with increased concentrations of MH induced AMPK phosphorylation in a dose-dependent manner that was accompanied by inhibition of phosphorylation of AKT and mTOR downstream effector protein S6. In addition, MH reduced phosphorylated STAT3 levels in vitro, which may correlate with MH and AMPK-mediated anti-inflammatory properties. Further, in vivo, MH administered alone significantly inhibited the growth of established MCF-7 tumors in nude mice by 84%, resulting in an observable reduction in tumor volume. Our findings highlight the need for further research into the use of natural compounds, such as MH, for antitumor efficacy and potential chemoprevention and investigation of molecular pathways underlying these actions.
- Open Access
- 12 June 2024
- Published by MDPI AG in Preprints.org
Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models
Manuka honey (MH) exhibits potential antitumor activity in preclinical models of a number of human cancers. Treatment in vitro with MH at concentrations ranging from 0.3-5.0% (w/v) led to significant dose-dependent inhibition of proliferation of human breast cancer MCF-7 cells, but anti-proliferative effects of MH were less pronounced in triple-negative MDA-MB-231 breast cancer cells. Effects of MH were also tested on non-malignant human mammary epithelial cells (HMEC) at 2.5% w/v, and it was found that MH reduced proliferation of MCF-7 cells but not that of HMEC. Notably, the antitumor activity of MH was in the range of that exerted by treatment of MCF-7 cells with the antiestrogen tamoxifen. Further, MH treatment stimulated apoptosis of MCF-7 cells in vitro, with most cells exhibiting acute and significant levels of apoptosis that correlated with PARP activation. Additionally, effects of MH induced activation of AMPK and inhibition of AKT/mTOR downstream signaling. Treatment of MCF7 cells with increased concentrations of MH induced AMPK phosphorylation in a dose dependent manner that was accompanied by inhibition of phosphorylation of AKT and mTOR downstream effector protein S6. In addition, MH reduced phosphorylated STAT3 levels in vitro which may correlate with MH and AMPK-mediated anti-inflammatory properties. Further, in vivo, MH administered alone significantly inhibited the growth of established MCF-7 tumors in nude mice by 84%, resulting in an observable reduction in tumor volume. Our findings highlight the need for further research into the use of natural compounds, such as MH, for antitumor efficacy and potential chemoprevention and investigation of molecular pathways underlying these actions.
- 12 June 2024
- Published by MDPI AG in Preprints.org
Open AccessManuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models
Manuka honey (MH) exhibits potential antitumor activity in preclinical models of a number of human cancers. Treatment in vitro with MH at concentrations ranging from 0.3-5.0% (w/v) led to significant dose-dependent inhibition of proliferation of human breast cancer MCF-7 cells, but anti-proliferative effects of MH were less pronounced in triple-negative MDA-MB-231 breast cancer cells. Effects of MH were also tested on non-malignant human mammary epithelial cells (HMEC) at 2.5% w/v, and it was found that MH reduced proliferation of MCF-7 cells but not that of HMEC. Notably, the antitumor activity of MH was in the range of that exerted by treatment of MCF-7 cells with the antiestrogen tamoxifen. Further, MH treatment stimulated apoptosis of MCF-7 cells in vitro, with most cells exhibiting acute and significant levels of apoptosis that correlated with PARP activation. Additionally, effects of MH induced activation of AMPK and inhibition of AKT/mTOR downstream signaling. Treatment of MCF7 cells with increased concentrations of MH induced AMPK phosphorylation in a dose dependent manner that was accompanied by inhibition of phosphorylation of AKT and mTOR downstream effector protein S6. In addition, MH reduced phosphorylated STAT3 levels in vitro which may correlate with MH and AMPK-mediated anti-inflammatory properties. Further, in vivo, MH administered alone significantly inhibited the growth of established MCF-7 tumors in nude mice by 84%, resulting in an observable reduction in tumor volume. Our findings highlight the need for further research into the use of natural compounds, such as MH, for antitumor efficacy and potential chemoprevention and investigation of molecular pathways underlying these actions.
- Open Access
- 29 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3200
An Exercise Immune Fitness Test to Unravel Disease Mechanisms—A Proof-of-Concept Heart Failure Study
Background: Cardiorespiratory fitness positively correlates with longevity and immune health. Regular exercise may provide health benefits by reducing systemic inflammation. In chronic disease conditions, such as chronic heart failure and chronic fatigue syndrome, mechanistic links have been postulated between inflammation, muscle weakness, frailty, catabolic/anabolic imbalance, and aberrant chronic activation of immunity with monocyte upregulation. We hypothesize that (1) temporal changes in transcriptome profiles of peripheral blood mononuclear cells during strenuous acute bouts of exercise using cardiopulmonary exercise testing are present in adult subjects, (2) these temporal dynamic changes are different between healthy persons and heart failure patients and correlate with clinical exercise-parameters and (3) they portend prognostic information. Methods: In total, 16 Heart Failure (HF) patients and 4 healthy volunteers (HV) were included in our proof-of-concept study. All participants underwent upright bicycle cardiopulmonary exercise testing. Blood samples were collected at three time points (TP) (TP1: 30 min before, TP2: peak exercise, TP3: 1 h after peak exercise). We divided 20 participants into 3 clinically relevant groups of cardiorespiratory fitness, defined by peak VO2: HV (n = 4, VO2 ≥ 22 mL/kg/min), mild HF (HF1) (n = 7, 14 < VO2 < 22 mL/kg/min), and severe HF (HF2) (n = 9, VO2 ≤ 14 mL/kg/min). Results: Based on the statistical analysis with 20–100% restriction, FDR correction (p-value 0.05) and 2.0-fold change across the three time points (TP1, TP2, TP3) criteria, we obtained 11 differentially expressed genes (DEG). Out of these 11 genes, the median Gene Expression Profile value decreased from TP1 to TP2 in 10 genes. The only gene that did not follow this pattern was CCDC181. By performing 1-way ANOVA, we identified 8/11 genes in each of the two groups (HV versus HF) while 5 of the genes (TTC34, TMEM119, C19orf33, ID1, TKTL2) overlapped between the two groups. We found 265 genes which are differentially expressed between those who survived and those who died. Conclusions: From our proof-of-concept heart failure study, we conclude that gene expression correlates with VO2 peak in both healthy individuals and HF patients, potentially by regulating various physiological processes involved in oxygen uptake and utilization during exercise. Multi-omics profiling may help identify novel biomarkers for assessing exercise capacity and prognosis in HF patients, as well as potential targets for therapeutic intervention to improve VO2 peak and quality of life. We anticipate that our results will provide a novel metric for classifying immune health.
- 29 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3200
Open AccessAn Exercise Immune Fitness Test to Unravel Disease Mechanisms—A Proof-of-Concept Heart Failure Study
Background: Cardiorespiratory fitness positively correlates with longevity and immune health. Regular exercise may provide health benefits by reducing systemic inflammation. In chronic disease conditions, such as chronic heart failure and chronic fatigue syndrome, mechanistic links have been postulated between inflammation, muscle weakness, frailty, catabolic/anabolic imbalance, and aberrant chronic activation of immunity with monocyte upregulation. We hypothesize that (1) temporal changes in transcriptome profiles of peripheral blood mononuclear cells during strenuous acute bouts of exercise using cardiopulmonary exercise testing are present in adult subjects, (2) these temporal dynamic changes are different between healthy persons and heart failure patients and correlate with clinical exercise-parameters and (3) they portend prognostic information. Methods: In total, 16 Heart Failure (HF) patients and 4 healthy volunteers (HV) were included in our proof-of-concept study. All participants underwent upright bicycle cardiopulmonary exercise testing. Blood samples were collected at three time points (TP) (TP1: 30 min before, TP2: peak exercise, TP3: 1 h after peak exercise). We divided 20 participants into 3 clinically relevant groups of cardiorespiratory fitness, defined by peak VO2: HV (n = 4, VO2 ≥ 22 mL/kg/min), mild HF (HF1) (n = 7, 14 < VO2 < 22 mL/kg/min), and severe HF (HF2) (n = 9, VO2 ≤ 14 mL/kg/min). Results: Based on the statistical analysis with 20–100% restriction, FDR correction (p-value 0.05) and 2.0-fold change across the three time points (TP1, TP2, TP3) criteria, we obtained 11 differentially expressed genes (DEG). Out of these 11 genes, the median Gene Expression Profile value decreased from TP1 to TP2 in 10 genes. The only gene that did not follow this pattern was CCDC181. By performing 1-way ANOVA, we identified 8/11 genes in each of the two groups (HV versus HF) while 5 of the genes (TTC34, TMEM119, C19orf33, ID1, TKTL2) overlapped between the two groups. We found 265 genes which are differentially expressed between those who survived and those who died. Conclusions: From our proof-of-concept heart failure study, we conclude that gene expression correlates with VO2 peak in both healthy individuals and HF patients, potentially by regulating various physiological processes involved in oxygen uptake and utilization during exercise. Multi-omics profiling may help identify novel biomarkers for assessing exercise capacity and prognosis in HF patients, as well as potential targets for therapeutic intervention to improve VO2 peak and quality of life. We anticipate that our results will provide a novel metric for classifying immune health.